CLOVER BIO-B (02197) Announces Positive Phase I Clinical Trial Data for Respiratory Combination Vaccine (RSV-hMPV-PIV3) and RSV Vaccine Booster in Elderly Population

Stock News10-14

CLOVER BIO-B (02197) announced positive preliminary data from two ongoing clinical trials based on the company's proprietary and fully validated Trimer-Tag vaccine development platform, evaluating the company's PreF respiratory combination vaccine candidates (RSV+hMPV±PIV3), including:

A Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in head-to-head comparison with SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) in elderly participants who had not previously received any RSV vaccine.

Additionally, a Phase I clinical trial conducted in the United States to evaluate head-to-head comparison of SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) versus AREXVY (GSK's RSV vaccine) for booster vaccination in elderly participants who had received their initial AREXVY vaccination at least two epidemic seasons prior to enrollment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189980496?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 18:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189980496","market":"hk","top_or_hot":-1,"title":"CLOVER BIO-B (02197) Announces Positive Phase I Clinical Trial Data for Respiratory Combination Vaccine (RSV-hMPV-PIV3) and RSV Vaccine Booster in Elderly Population","media":"Stock News","content":"<p>CLOVER BIO-B (02197) announced positive preliminary data from two ongoing clinical trials based on the company's proprietary and fully validated Trimer-Tag vaccine development platform, evaluating the company's PreF respiratory combination vaccine candidates (RSV+hMPV±PIV3), including:</p>\n<p>A Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in head-to-head comparison with SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) in elderly participants who had not previously received any RSV vaccine.</p>\n<p>Additionally, a Phase I clinical trial conducted in the United States to evaluate head-to-head comparison of SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) versus AREXVY (GSK's RSV vaccine) for booster vaccination in elderly participants who had received their initial AREXVY vaccination at least two epidemic seasons prior to enrollment.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOVER BIO-B (02197) Announces Positive Phase I Clinical Trial Data for Respiratory Combination Vaccine (RSV-hMPV-PIV3) and RSV Vaccine Booster in Elderly Population</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOVER BIO-B (02197) Announces Positive Phase I Clinical Trial Data for Respiratory Combination Vaccine (RSV-hMPV-PIV3) and RSV Vaccine Booster in Elderly Population\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-14 18:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOVER BIO-B (02197) announced positive preliminary data from two ongoing clinical trials based on the company's proprietary and fully validated Trimer-Tag vaccine development platform, evaluating the company's PreF respiratory combination vaccine candidates (RSV+hMPV±PIV3), including:</p>\n<p>A Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in head-to-head comparison with SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) in elderly participants who had not previously received any RSV vaccine.</p>\n<p>Additionally, a Phase I clinical trial conducted in the United States to evaluate head-to-head comparison of SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) versus AREXVY (GSK's RSV vaccine) for booster vaccination in elderly participants who had received their initial AREXVY vaccination at least two epidemic seasons prior to enrollment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159646","symbol_name":"疫苗","start_time":0,"source_url":"","article_id":"1189980496","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189980496","pubTimestamp":1760436980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOVER BIO-B (02197) announced positive preliminary data from two ongoing clinical trials based on the company's proprietary and fully validated Trimer-Tag vaccine development platform, evaluating...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","BK1161":"生物科技","02197":"三叶草生物-B"},"translate_title":"三叶草生物-B(02197)公布呼吸道联合疫苗(RSV-hMPV-PIV3)及RSV疫苗加强剂在老年人群中的I期临床试验阳性数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"02197":1},"content_text":"CLOVER BIO-B (02197) announced positive preliminary data from two ongoing clinical trials based on the company's proprietary and fully validated Trimer-Tag vaccine development platform, evaluating the company's PreF respiratory combination vaccine candidates (RSV+hMPV±PIV3), including:\nA Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) in head-to-head comparison with SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) in elderly participants who had not previously received any RSV vaccine.\nAdditionally, a Phase I clinical trial conducted in the United States to evaluate head-to-head comparison of SCB-1019 (CLOVER BIO-B's RSV vaccine candidate) versus AREXVY (GSK's RSV vaccine) for booster vaccination in elderly participants who had received their initial AREXVY vaccination at least two epidemic seasons prior to enrollment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189980496","isCrawlerRequest":true}